We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Long-term survival with allogeneic stem cell transplant and donor lymphocyte infusion following salvage therapy with anti-CD52 monoclonal antibody (Campath) in a patient with alpha/beta hepatosplenic T-cell non-Hodgkin's lymphoma.
- Authors
Chanan-Khan, Asher; Islam, Tariq; Alam, Arif; Miller, Kena C; Gibbs, John; Barcos, Maurice; Czuczman, Myron S; Paplham, Pamela; Hahn, Theresa; McCarthy, Philip
- Abstract
Hepatosplenic T-cell non-Hodgkin's lymphoma (HSTCL) is a rare, aggressive form of NHL, with a median survival of approximately 8 months. We were able to successfully induce complete remission in a patient with alpha/beta HSTCL who was refractory to multiple prior chemotherapy regimens, using the humanized anti-CD52 monoclonal antibody alemtuzumab (Campath). Once disease was controlled, the patient was able to undergo allogeneic stem cell transplantation (SCT), which resulted in complete remission. Furthermore, upon relapse, we were able to re-induce complete clinical and molecular remission with donor lymphocyte infusions. At Day 655 (post-SCT), the patient remains in complete remission. These data suggest a potential role for alemtuzumab and allogeneic SCT in the treatment of T-cell NHL.
- Publication
Leukemia & lymphoma, 2004, Vol 45, Issue 8, p1673
- ISSN
1042-8194
- Publication type
Journal Article
- DOI
10.1080/10428190310001609924